For weight loss specifically, Zepbound has shown substantial results in clinical trials, where patients lost an average of 16.1 kg to 23.6 kg over 72 weeks, depending on the dose
Adding the second receptor improved weight loss from roughly 15% to 22.5% in clinical trials (Jastreboff et al., NEJM 2022)
Therefore, the initiation of therapy with GLP-1RAs contributes to significant weight loss
In addition to measurements and numbers, pay attention to how you feel on a daily basis
Most Commonly Reported Side Effects Nausea Diarrhea Vomiting Constipation Decreased appetite Injection site reactions Serious but less common risks include pancreatitis, gallbladder disease, and a possible risk of thyroid C-cell tumors based on animal studies
Following resolution of nationwide shortages, the FDA ended its temporary enforcement discretion, meaning these medications may now only be compounded under limited, legally defined circumstances . On February 21, 2025 , the U.S